Top

Published in:

Open Access 01-12-2022 | Escherichia Coli | Research

Gut microbiota in the early stage of Crohn’s disease has unique characteristics

Authors: Xianzong Ma, Xiaojuan Lu, Wenyu Zhang, Lang Yang, Dezhi Wang, Junfeng Xu, Yan Jia, Xin Wang, Hui Xie, Shu Li, Mingjie Zhang, Yuqi He, Peng Jin, Jianqiu Sheng

Published in: Gut Pathogens | Issue 1/2022

Abstract

Background

Emerging evidence suggests that gut microbiota plays a predominant role in Crohn’s disease (CD). However, the microbiome alterations in the early stage of CD patients still remain unclear. The present study aimed to identify dysbacteriosis in patients with early CD and explore specific gut bacteria related to the progression of CD.

Methods

This study was nested within a longitudinal prospective Chinese CD cohort, and it included 18 early CD patients, 22 advanced CD patients and 30 healthy controls. The microbiota communities were investigated using high-throughput Illumina HiSeq sequencing targeting the V3–V4 region of 16S ribosomal DNA (rDNA) gene. The relationship between the gut microbiota and clinical characteristics of CD was analyzed.

Results

Differential microbiota compositions were observed in CD samples (including early and advanced CD samples) and healthy controls samples. Notably, Lachnospiracea_incertae_sedis and Parabacteroides were enriched in the early CD patients, Escherichia/Shigella, Enterococcus and Proteus were enriched in the advanced CD patients, and Roseburia, Gemmiger, Coprococcus, Ruminococcus 2, Butyricicoccus, Dorea, Fusicatenibacter, Anaerostipes, Clostridium IV were enriched in the healthy controls [LDA score (log10) > 2]. Furthermore, Kruskal–Wallis Rank sum test results showed that Blautia, Clostridium IV, Coprococcus, Dorea, Fusicatenibacter continued to significantly decrease in early and advanced CD patients, and Escherichia/Shigella and Proteus continued to significantly increase compared with healthy controls (P < 0.05). The PICRUSt analysis identified 16 remarkably different metabolic pathways [LDA score (log10) > 2]. Some genera were significantly correlated with various clinical parameters, such as fecal calprotectin, erythrocyte sedimentation rate, C-reactive protein, gland reduce, goblet cells decreased, clinical symptoms (P < 0.05).

Conclusions

Dysbacteriosis occurs in the early stage of CD and is associated with the progression of CD. This data provides a foundation that furthers the understanding of the role of gut microbiota in CD’s pathogenesis.

Available only for authorised users

Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–94. https://doi.org/10.1053/j.gastro.2011.01.055.CrossRef

Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. Gut. 2010;59(9):1200–6. https://doi.org/10.1136/gut.2009.202101.CrossRef

Ng SC, Kaplan GG, Tang W, Banerjee R, Adigopula B, Underwood FE, et al. Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in Asia-Pacific. Am J Gastroenterol. 2019;114(1):107–15. https://doi.org/10.1038/s41395-018-0233-2.CrossRef

Sorrentino D, Nguyen VQ, Chitnavis MV. Capturing the biologic onset of inflammatory bowel diseases: impact on translational and clinical science. Cells. 2019;8(6):548. https://doi.org/10.3390/cells8060548.CrossRef

Torres J, Burisch J, Riddle M, Dubinsky M, Colombel JF. Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. Gut. 2016;65(7):1061–9. https://doi.org/10.1136/gutjnl-2016-311785.CrossRef

Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology. 2017;152(2):327-39.e4. https://doi.org/10.1053/j.gastro.2016.10.012.CrossRef

Simões CD, Maganinho M, Sousa AS. FODMAPs, inflammatory bowel disease and gut microbiota: updated overview on the current evidence. Eur J Nutr. 2022;61(3):1187–98. https://doi.org/10.1007/s00394-021-02755-1.CrossRef

Pittayanon R, Lau JT, Leontiadis GI, Tse F, Yuan Y, Surette M, et al. Differences in gut microbiota in patients with vs without inflammatory bowel diseases: a systematic review. Gastroenterology. 2019. https://doi.org/10.1053/j.gastro.2019.11.294.CrossRef

Alam MT, Amos G, Murphy A, Murch S, Wellington E, Arasaradnam RP. Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. Gut Pathog. 2020;12:1. https://doi.org/10.1186/s13099-019-0341-6.CrossRef

10.

Lee M, Chang EB. Inflammatory Bowel Diseases (IBD) and the microbiome-searching the crime scene for clues. Gastroenterology. 2021;160(2):524–37. https://doi.org/10.1053/j.gastro.2020.09.056.CrossRef

11.

Rajca S, Grondin V, Louis E, Vernier-Massouille G, Grimaud JC, Bouhnik Y, et al. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn’s disease. Inflamm Bowel Dis. 2014;20(6):978–86. https://doi.org/10.1097/MIB.0000000000000036.CrossRef

12.

Schäffler H, Herlemann DP, Klinitzke P, Berlin P, Kreikemeyer B, Jaster R, et al. Vitamin D administration leads to a shift of the intestinal bacterial composition in Crohn’s disease patients, but not in healthy controls. J Dig Dis. 2018;19(4):225–34. https://doi.org/10.1111/1751-2980.12591.CrossRef

13.

Dey N, Soergel DA, Repo S, Brenner SE. Association of gut microbiota with post-operative clinical course in Crohn’s disease. BMC Gastroenterol. 2013;13:131. https://doi.org/10.1186/1471-230X-13-131.CrossRef

14.

De Cruz P, Kang S, Wagner J, Buckley M, Sim WH, Prideaux L, et al. Association between specific mucosa-associated microbiota in Crohn’s disease at the time of resection and subsequent disease recurrence: a pilot study. J Gastroenterol Hepatol. 2015;30(2):268–78. https://doi.org/10.1111/jgh.12694.CrossRef

15.

Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon. Gut. 2003;52(2):237–42. https://doi.org/10.1136/gut.52.2.237.CrossRef

16.

Scanlan PD, Shanahan F, O’Mahony C, Marchesi JR. Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn’s disease. J Clin Microbiol. 2006;44(11):3980–8. https://doi.org/10.1128/JCM.00312-06.CrossRef

17.

Andoh A, Kobayashi T, Kuzuoka H, Tsujikawa T, Suzuki Y, Hirai F, et al. Characterization of gut microbiota profiles by disease activity in patients with Crohn’s disease using data mining analysis of terminal restriction fragment length polymorphisms. Biomed Rep. 2014;2(3):370–3. https://doi.org/10.3892/br.2014.252.CrossRef

18.

Wills ES, Jonkers DM, Savelkoul PH, Masclee AA, Pierik MJ, Penders J. Fecal microbial composition of ulcerative colitis and Crohn’s disease patients in remission and subsequent exacerbation. PLoS ONE. 2014;9(3): e90981. https://doi.org/10.1371/journal.pone.0090981.CrossRef

19.

Galazzo G, Tedjo DI, Wintjens D, Savelkoul P, Masclee A, Bodelier A, et al. Faecal microbiota dynamics and their relation to disease course in Crohn’s disease. J Crohns Colitis. 2019;13(10):1273–82. https://doi.org/10.1093/ecco-jcc/jjz049.CrossRef

20.

Pascal V, Pozuelo M, Borruel N, Casellas F, Campos D, Santiago A, et al. A microbial signature for Crohn’s disease. Gut. 2017;66(5):813–22. https://doi.org/10.1136/gutjnl-2016-313235.CrossRef

21.

De Musis C, Granata L, Dallio M, Miranda A, Gravina AG, Romano M. Inflammatory bowel diseases: the role of gut microbiota. Curr Pharm Des. 2020;26(25):2951–61. https://doi.org/10.2174/1381612826666200420144128.CrossRef

22.

Peyrin-Biroulet L, Billioud V, D’Haens G, Panaccione R, Feagan B, Panés J, et al. Development of the Paris definition of early Crohn’s disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012;107(12):1770–6. https://doi.org/10.1038/ajg.2012.117.CrossRef

23.

Langille MG, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013;31(9):814–21. https://doi.org/10.1038/nbt.2676.CrossRef

24.

Douglas GM, Maffei VJ, Zaneveld JR, Yurgel SN, Brown JR, Taylor CM, et al. PICRUSt2 for prediction of metagenome functions. Nat Biotechnol. 2020;38(6):685–8. https://doi.org/10.1038/s41587-020-0548-6.CrossRef

25.

Nguyen VQ, Jiang D, Hoffman SN, Guntaka S, Mays JL, Wang A, et al. Impact of diagnostic delay and associated factors on clinical outcomes in a U.S. inflammatory bowel disease cohort. Inflamm Bowel Dis. 2017;23(10):1825–31. https://doi.org/10.1097/MIB.0000000000001257.CrossRef

26.

Ma HQ, Yu TT, Zhao XJ, Zhang Y, Zhang HJ. Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease. World J Gastroenterol. 2018;24(13):1464–77. https://doi.org/10.3748/wjg.v24.i13.1464.CrossRef

27.

Wright EK, Kamm MA, Teo SM, Inouye M, Wagner J, Kirkwood CD. Recent advances in characterizing the gastrointestinal microbiome in Crohn’s disease: a systematic review. Inflamm Bowel Dis. 2015;21(6):1219–28. https://doi.org/10.1097/MIB.0000000000000382.CrossRef

28.

Vester-Andersen MK, Mirsepasi-Lauridsen HC, Prosberg MV, Mortensen CO, Träger C, Skovsen K, et al. Increased abundance of proteobacteria in aggressive Crohn’s disease seven years after diagnosis. Sci Rep. 2019;9(1):13473. https://doi.org/10.1038/s41598-019-49833-3.CrossRef

29.

Rehman A, Lepage P, Nolte A, Hellmig S, Schreiber S, Ott SJ. Transcriptional activity of the dominant gut mucosal microbiota in chronic inflammatory bowel disease patients. J Med Microbiol. 2010;59(Pt 9):1114–22. https://doi.org/10.1099/jmm.0.021170-0.CrossRef

30.

Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Fölsch UR, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53(5):685–93. https://doi.org/10.1136/gut.2003.025403.CrossRef

31.

Delday M, Mulder I, Logan ET, Grant G. Bacteroides thetaiotaomicron ameliorates colon inflammation in preclinical models of Crohn’s disease. Inflamm Bowel Dis. 2019;25(1):85–96. https://doi.org/10.1093/ibd/izy281.CrossRef

32.

Walker AW, Sanderson JD, Churcher C, Parkes GC, Hudspith BN, Rayment N, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011;11:7. https://doi.org/10.1186/1471-2180-11-7.CrossRef

33.

Zitomersky NL, Atkinson BJ, Franklin SW, Mitchell PD, Snapper SB, Comstock LE, et al. Characterization of adherent bacteroidales from intestinal biopsies of children and young adults with inflammatory bowel disease. PLoS ONE. 2013;8(6):e63686. https://doi.org/10.1371/journal.pone.0063686.CrossRef

34.

Dziarski R, Park SY, Kashyap DR, Dowd SE, Gupta D. Pglyrp-regulated gut microflora Prevotella falsenii, parabacteroides distasonis and Bacteroides eggerthii enhance and Alistipes finegoldii attenuates colitis in mice. PLoS ONE. 2016;11(1):e0146162. https://doi.org/10.1371/journal.pone.0146162.CrossRef

35.

Yang F, Kumar A, Davenport KW, Kelliher JM, Ezeji JC, Good CE, et al. Complete genome sequence of a Parabacteroides distasonis strain (CavFT hAR46) isolated from a gut wall-cavitating microlesion in a patient with severe crohn’s disease. Microbiol Resour Announc. 2019. https://doi.org/10.1128/MRA.00585-19.CrossRef

36.

Mackner LM, Hatzakis E, Allen JM, Davies RH, Kim SC, Maltz RM, et al. Fecal microbiota and metabolites are distinct in a pilot study of pediatric Crohn’s disease patients with higher levels of perceived stress. Psychoneuroendocrinology. 2020;111:104469. https://doi.org/10.1016/j.psyneuen.2019.104469.CrossRef

37.

Huycke MM, Abrams V, Moore DR. Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. Carcinogenesis. 2002;23(3):529–36. https://doi.org/10.1093/carcin/23.3.529.CrossRef

38.

Quince C, Ijaz UZ, Loman N, Eren AM, Saulnier D, Russell J, et al. Extensive modulation of the fecal metagenome in children with Crohn’s disease during exclusive enteral nutrition. Am J Gastroenterol. 2015;110(12):1718–29. https://doi.org/10.1038/ajg.2015.357. (quiz 1730).CrossRef

39.

Kowalska-Duplaga K, Gosiewski T, Kapusta P, Sroka-Oleksiak A, Wędrychowicz A, Pieczarkowski S, et al. Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn’s disease. Sci Rep. 2019;9(1):18880. https://doi.org/10.1038/s41598-019-55290-9.CrossRef

40.

Cummings JH, Macfarlane GT. The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol. 1991;70(6):443–59. https://doi.org/10.1111/j.1365-2672.1991.tb02739.x.CrossRef

41.

Phalipon A, Sansonetti PJ. Shigellosis: innate mechanisms of inflammatory destruction of the intestinal epithelium, adaptive immune response, and vaccine development. Crit Rev Immunol. 2003;23(5–6):371–401. https://doi.org/10.1615/critrevimmunol.v23.i56.20.CrossRef

42.

Iebba V, Aloi M, Civitelli F, Cucchiara S. Gut microbiota and pediatric disease. Dig Dis. 2011;29(6):531–9. https://doi.org/10.1159/000332969.CrossRef

43.

Darfeuille-Michaud A, Neut C, Barnich N, Lederman E, Di Martino P, Desreumaux P, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn’s disease. Gastroenterology. 1998;115(6):1405–13. https://doi.org/10.1016/s0016-5085(98)70019-8.CrossRef

44.

Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology. 2004;127(2):412–21. https://doi.org/10.1053/j.gastro.2004.04.061.CrossRef

45.

Hold GL, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhya I. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years. World J Gastroenterol. 2014;20(5):1192–210. https://doi.org/10.3748/wjg.v20.i5.1192.CrossRef

46.

Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, et al. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in crohn’s disease. Digestion. 2016;93(1):59–65. https://doi.org/10.1159/000441768.CrossRef

47.

Gasaly N, de Vos P, Hermoso MA. Impact of bacterial metabolites on gut barrier function and host immunity: a focus on bacterial metabolism and its relevance for intestinal inflammation. Front Immunol. 2021;12:658354. https://doi.org/10.3389/fimmu.2021.658354.CrossRef

48.

Valles-Colomer M, Falony G, Darzi Y, Tigchelaar EF, Wang J, Tito RY, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. 2019;4(4):623–32. https://doi.org/10.1038/s41564-018-0337-x.CrossRef

49.

Metwaly A, Reitmeier S, Haller D. Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders. Nat Rev Gastroenterol Hepatol. 2022. https://doi.org/10.1038/s41575-022-00581-2.CrossRef

50.

Ma XZ, Lu XJ, Jin P, et al. Follow-up of ileocecal inflammatory lesions and its significance in early diagnosis of Crohn’s disease. Chin J Dig. 2020;40(5):306–13. https://doi.org/10.3760/cma.j.cn311367-20200121-00030.306-13.CrossRef

51.

Church DL, Cerutti L, Gürtler A, Griener T, Zelazny A, Emler S. Performance and application of 16S rRNA gene cycle sequencing for routine identification of bacteria in the clinical microbiology laboratory. Clin Microbiol Rev. 2020;33(4):e00053-19. https://doi.org/10.1128/CMR.00053-19.CrossRef

52.

Costea PI, Zeller G, Sunagawa S, Pelletier E, Alberti A, Levenez F, et al. Towards standards for human fecal sample processing in metagenomic studies. Nat Biotechnol. 2017;35(11):1069–76. https://doi.org/10.1038/nbt.3960.CrossRef

53.

Weiss S, Xu ZZ, Peddada S, Amir A, Bittinger K, Gonzalez A, et al. Normalization and microbial differential abundance strategies depend upon data characteristics. Microbiome. 2017;5(1):27. https://doi.org/10.1186/s40168-017-0237-y.CrossRef

54.

Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021;15(6):879–913. https://doi.org/10.1093/ecco-jcc/jjab052.CrossRef

Title: Gut microbiota in the early stage of Crohn’s disease has unique characteristics
Authors: Xianzong Ma
Xiaojuan Lu
Wenyu Zhang
Lang Yang
Dezhi Wang
Junfeng Xu
Yan Jia
Xin Wang
Hui Xie
Shu Li
Mingjie Zhang
Yuqi He
Peng Jin
Jianqiu Sheng
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Escherichia Coli
Crohn's Disease
Clostridium
Respiratory Microbiota
Published in: Gut Pathogens / Issue 1/2022
Electronic ISSN: 1757-4749
DOI: https://doi.org/10.1186/s13099-022-00521-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Analysis of gastric microbiota and Helicobacter pylori infection in gastroesophageal reflux disease

Rapid screening for antigenic characterization of GII.17 norovirus strains with variations in capsid gene

Influence of lincomycin-spectinomycin treatment on the outcome of Enterococcus cecorum infection and on the cecal microbiota in broilers

Virulence and phylogenetic groups of Escherichia coli cultured from raw sewage in Kuwait

The effect of Campylobacter jejuni and Campylobacter coli colonization on the gut morphology, functional integrity, and microbiota composition of female turkeys

Fusobacterium nucleatum promotes the development of acute liver failure by inhibiting the NAD+ salvage metabolic pathway

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage